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background
 
Antibodies against HLA antigens cause refractory allograft rejection with vasculopathy
in some, but not all, patients.
 
methods
 
We studied 33 kidney-transplant recipients who had refractory vascular rejection.
Thirteen had donor-specific anti-HLA antibodies, whereas 20 did not. Malignant hyper-
tension was present in 16 of the patients without anti-HLA antibodies, 4 of whom had
seizures. The remaining 17 patients had no malignant hypertension. We hypothesized
that activating antibodies targeting the angiotensin II type 1 (AT
 
1
 
) receptor might be
involved.
 
results
 
Activating IgG antibodies targeting the AT
 
1
 
 receptor were detected in serum from all
16 patients with malignant hypertension and without anti-HLA antibodies, but in no
other patients. These receptor-activating antibodies are subclass IgG1 and IgG3 anti-
bodies that bind to two different epitopes on the second extracellular loop of the AT
 
1
 
receptor. Tissue factor expression was increased in renal-biopsy specimens from pa-
tients with these antibodies. In vitro stimulation of vascular cells with an AT
 
1
 
-receptor–
activating antibody induced phosphorylation of ERK 1/2 kinase and increased the DNA
binding activity of the transcription factors activator protein 1 (AP-1) and nuclear fac-
tor-
 
k
 
B. The AT
 
1
 
 antagonist losartan blocked agonistic AT
 
1
 
-receptor antibody–mediat-
ed effects, and passive antibody transfer induced vasculopathy and hypertension in a
rat kidney-transplantation model.
 
conclusions
 
A non-HLA, AT
 
1
 
-receptor–mediated pathway may contribute to refractory vascular re-
jection, and affected patients might benefit from removal of AT
 
1
 
-receptor antibodies or
from pharmacologic blockade of AT
 
1
 
 receptors.
abstract
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any aspects of t-cell–mediated
 
responses in allograft rejection have
been elucidated, yet humoral mecha-
nisms are relatively unexplored. Vascular rejection
that is refractory to intensified immunosuppression
is the most important predictor of early and late
graft loss.
 
1
 
 The association of antidonor humoral
reactivity against HLA antigens and vascular rejec-
tion has been established.
 
2
 
 Other targets of the
allograft-directed host response remain elusive.
However, alloantibodies against the polymorphic
non-HLA system were found in serum obtained be-
fore transplantation from patients in whom refrac-
tory rejection developed after they received kidney
transplants from HLA-identical siblings.
 
3
 
 Allograft
endothelium may be a primary target of the cyto-
pathic actions of non-HLA antibodies, triggering
endothelial-cell activation or apoptosis.
 
4,5
 
 Identi-
fication of non-HLA antigens that are relevant to
rejection might provide insight into underlying
mechanisms, define risk-related phenotypes, and
facilitate the development of specific therapies.
We studied kidney-transplant recipients who had
severe allograft dysfunction but did not have anti-
HLA antibodies; in these patients, rejection was in-
variably accompanied by accelerated hypertension,
and even convulsions, in a manner reminiscent of
preeclampsia. In fact, the first patient we examined
in this group (the index patient) had had pre-
eclampsia 16 years earlier. Immunologic similarities
between graft rejection and fetal survival in preg-
nancies complicated by preeclampsia are well rec-
ognized.
 
6
 
 We previously reported that agonistic
antibodies that target the angiotensin II type 1
(AT
 
1
 
) receptor may develop in women with pre-
eclampsia after the 20th week of gestation,
 
7 
 
and we
observed agonistic AT
 
1
 
-receptor activity in nine
kidney-transplant recipients during an episode of
rejection.
 
8
 
 We then reasoned that similar mecha-
nisms might be present in refractory allograft re-
jection and initiated a comprehensive investigation
of this issue.
 
study patients and biopsies
 
We studied all patients with steroid-refractory acute
renal-allograft rejection seen among those who re-
ceived kidney transplants at the Charité University
Hospital Campus Mitte in Berlin from January 1,
2000, through July 31, 2004. Serum samples were
obtained prospectively from all patients during re-
jection episodes and were screened for donor-
specific anti-HLA antibodies and also analyzed for
agonistic antibodies targeting the AT
 
1
 
 receptor. Se-
rum samples from patients with steroid-refractory
acute vascular rejection from three collaborating
centers (the Charité University Hospital Campus
Virchow Clinic, and the University Hospital Erlan-
gen–Nürnberg, both in Germany, and the Ospedale
Civile in Bergamo, Italy) were also examined. Writ-
ten informed consent to use serum samples for
research purposes was obtained from each patient
while he or she was awaiting transplantation. The
institutional review board of Charité University
Hospital Berlin approved the protocols.
Allograft-biopsy specimens were processed by
standard techniques and graded according to the
Banff 97 classification, with updated scoring of
the degree of humoral rejection.
 
9,10
 
 Biopsy speci-
mens were stained with polyclonal antibodies for
C4d (Biomedica)
 
11,12
 
 and tissue factor (provided by
T. Luther, Dresden).
Initial immunosuppressive therapy consisted
of a calcineurin inhibitor, mycophenolate mofetil,
methylprednisolone, and antibody against inter-
leukin-2 receptor for induction. Patients who were
positive for donor-specific anti-HLA antibodies or
C4d or who had vascular rejection manifested as
endarteritis or necrotizing vasculitis with fibrinoid
necrosis were treated with plasmapheresis together
with intravenous immune globulin. Patients initial-
ly treated with cyclosporine were switched to high-
dose tacrolimus when refractory rejection was de-
tected.
 
bioassays and analysis of epitopes
 
Patients’ serum samples were examined for the
presence of AT
 
1
 
-receptor–activating IgG in a func-
tional bioassay that involves spontaneously beating
cultured neonatal-rat cardiomyocytes that express
several G-protein–coupled receptors, including the
AT
 
1
 
 receptor. Changes in the activation state of the
cells is measured directly by counting the beating
rate by means of computerized image analysis. Iso-
lation, cultivation, and detection procedures have
been described in detail previously.
 
13
 
 The dose–
response relationship between activating IgG or
angiotensin II concentration and the spontaneous
beating rate is linear.
To study the specificity of the AT
 
1 
 
receptor–
mediated response, IgG-stimulated cells were treat-
ed with an AT
 
1
 
-receptor blocker or angiotensin II
type 2 (AT
 
2
 
)–receptor blocker. Short, overlapping
methods
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synthetic peptides corresponding to the sequence
of the second extracellular loop of the AT
 
1
 
 receptor
were used for identification of epitopes. To identify
the IgG subclass, IgG from 10 patients from whom
sufficient serum was available were treated with
murine monoclonal antihuman IgG1, IgG2, IgG3,
and IgG4 antibodies.
 
surface-plasmon-resonance analysis
 
Binding of AT
 
1
 
-receptor antibody was verified and
quantified by surface-plasmon-resonance analysis
(BIAcore). The IgG fraction from affected patients
or control human IgG was allowed to pass over bio-
tinylated peptides loaded on a streptavidin-immo-
bilized chip in a biosensor (BIAcore) at different
flow rates. After the association phase and the dis-
sociation phase, the relative increase in response
of AT
 
1
 
-receptor peptide and control peptide (
 
b
 
2
 
-
adrenergic receptor) flow channels was determined.
The kinetic variables were calculated with BIA eval-
uation software (Biosensor, version 3.1).
 
assays
 
Human coronary-artery endothelial cells and vas-
cular smooth-muscle cells were stimulated with
AT
 
1
 
-receptor antibodies in the presence or absence
of AT
 
1
 
-receptor blocker or AT
 
2
 
-receptor blocker.
Protein extraction, sodium dodecyl sulfate–poly-
acrylamide-gel electrophoresis, and membrane
treatment were performed as described by Dechend
et al.
 
14
 
 Primary antibodies against polyclonal ex-
tracellular signal–regulated kinase (ERK) 1/2 and
phosphorylated ERK 1/2 were used. Triplicate ex-
periments with six patients’ IgG preparations were
performed. Electromobility-shift assays in vascular
smooth-muscle cells stimulated with angiotensin
II, AT
 
1
 
-receptor antibodies, or control IgG were
performed as described previously.
 
14
 
animal model of kidney transplantation
 
The low-responder Fischer 344-to-Lewis life sup-
porting rat kidney-transplantation model was used
to test the physiological effects of various antibod-
ies. AT
 
1
 
-receptor antibodies (a pool derived from
two donors), control IgG, or vehicle was continu-
ously infused into recipient rats by means of intra-
peritoneal, seven-day-release, osmotic minipumps
(Alzet, Charles River Laboratories). After implanta-
tion of the minipumps, one kidney was transplant-
ed into each rat (cold-ischemia time was two hours),
and kidneys were harvested after seven days (n=4
per treatment group).
 
15
 
 For continuous blood-
pressure monitoring, telemetric transmitters were
placed into the abdominal aortas of six addition-
al rodent recipients, before transplantation. The
histologic features of the rat allografts were ana-
lyzed after harvesting with standard techniques.
Direct immunofluorescence with fluorescein iso-
thiocyanate–labeled antihuman IgG (Dako) was
used to determine intragraft binding of AT
 
1
 
-recep-
tor antibodies; cryosections were counterstained
with 4',6-diamidino-2-phenylindole dihydrochlo-
ride (Vector).
 
statistical analysis
 
Continuous data are presented as medians (with
ranges). We performed comparisons between
groups with use of Fisher’s exact test for categori-
cal values and the Mann–Whitney U test for contin-
uous variables.
Thirty-three patients with steroid-refractory rejec-
tion were identified (23 at Charité University Hospi-
tal Campus Mitte and 10 at collaborating centers).
Thirteen had detectable donor-specific anti-HLA
antibodies. Sixteen patients who did not have donor-
specific anti-HLA antibodies had malignant hy-
pertension, followed by convulsions in four. Four
patients had neither donor-specific anti-HLA anti-
bodies nor malignant hypertension. Figure 1 shows
representative biopsy specimens from patients with
malignant hypertension and refractory rejection
who had no donor-specific anti-HLA antibodies;
these showed either endarteritis (Fig. 1A) or fibrin-
oid necrosis (Fig. 1B). Patients whose biopsy spec-
imens had evidence of fibrinoid necrosis under-
went magnetic resonance angiography studies that
showed multiple perfusion defects consistent with
cortical infarctions (Fig. 1C). Subsequently, pa-
tients with anti-HLA antibodies had substantially
better graft survival than did those who had malig-
nant hypertension but did not have anti-HLA anti-
bodies (Fig. 1D).
We studied the AT
 
1
 
-receptor agonistic response
and IgG subclasses with a bioassay that records the
chronotropic response (the increase in the number
of beats per minute) of spontaneously beating neo-
natal-rat cardiomyocytes when exposed to immu-
noglobulin from patients. Analysis of serum ob-
tained from the 13 anti-HLA–positive patients and
from the 16 anti-HLA–negative patients with ma-
lignant hypertension before transplantation and at
results
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the time of rejection indicated differences between
the groups. Figure 2A demonstrates a mean in-
crease of 26 to 30 beats per minute in cells exposed
to IgG obtained before transplantation or at the
time of rejection from patients without anti-HLA
antibodies. Serum from 13 patients with humoral
rejection mediated by donor-specific anti-HLA
antibodies did not induce such increases. Immu-
noglobulin from the four remaining patients, who
had steroid-refractory rejection without malignant
hypertension or HLA-antibodies, did not induce a
response (data not shown).
All 16 patients whose serum led to an increased
chronotropic response were screened for heredi-
tary and autoimmune causes of thrombophilia as
a possible trigger of the observed thrombotic angi-
opathy; all tests were negative, as were additional
serologic tests for autoimmune disorders. Acute
infection with cytomegalovirus was ruled out by
pp65 antigen and reverse-transcriptase polymerase-
chain-reaction analysis (in three participating Ger-
man centers) or on clinical grounds (in Bergamo,
Italy).
Specific angiotensin II–receptor antagonists
were used to test whether the agonistic response to
patients’ IgG was specific for the AT
 
1
 
 receptor.
Losartan, but not the AT
 
2
 
-receptor antagonist PD
123319, abolished the functional bioassay response
(Fig. 2B). Angiotensin II and IgG from patients
achieved results in the bioassay. Thus, IgG fractions
of our patients’ serum contained AT
 
1
 
-receptor anti-
bodies.
The demographic data from the 16 patients
who were positive for AT
 
1
 
-receptor antibodies
 
Figure 1. Features of Refractory Rejection in Patients without Donor-Specific Anti-HLA Antibodies.
 
Biopsy specimens from representative patients (stained with hematoxylin and eosin) show endarteritis (Panel A) and 
fibrinoid changes and necrosis in the wall of the interlobular artery, with a mural thrombus consistent with acute vas-
cular rejection (Panel B). A magnetic resonance image of the kidney (Panel C) shows multiple perfusion defects consis-
tent with the occurrence of cortical infarctions. The graph in Panel D demonstrates accelerated allograft loss in patients 
who had refractory vascular rejection with non-HLA antibodies, compared with patients who had vascular rejection and 
donor-specific anti-HLA antibodies. AT
 
1
 
R-AA denotes AT
 
1
 
-receptor antibodies.
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were compared with those for the 13 patients with
donor-specific anti-HLA-antibodies. As shown in
Table 1, patients with anti-HLA antibodies were
more likely to have staining for C4d in their renal-
biopsy specimens and had less rapid allograft loss.
Otherwise, there were no significant differences
in clinical or demographic characteristics between
the two groups.
To estimate the incidence and prevalence of ste-
roid-refractory allograft rejections in patients with
AT
 
1
 
-receptor antibodies, we studied all episodes of
rejection that occurred after the 278 consecutive
kidney transplantations performed at the Charité
University Hospital Campus Mitte in Berlin between
January 1, 2000, and July 31, 2004. During this pe-
riod, 119 biopsy-proved episodes of rejection were
 
Figure 2. Antibody Detection and Agonistic Activity as Indicated by a Bioassay Based on the Chronotropic Response 
of Neonatal-Rat Cardiomyocytes, Measured by the Increase in Beats per Minute.
 
Exposure to IgG from patients with refractory vascular rejection who did not have anti-HLA antibodies but did have 
AT
 
1
 
-receptor antibodies(AT
 
1
 
-R-AA–positive/anti-HLA–negative) before transplantation (13 of 16) or at the time of rejec-
tion (16 of 16) increased the rate of beating; IgG obtained before transplantation or at the time of rejection from patients 
with steroid-refractory vascular rejection due to anti-HLA antibodies (13 patients)(AT
 
1
 
R-AA–negative/anti-HLA–positive) 
had no effect on the rate of beating (Panel A). The response is AT
 
1
 
-receptor–specific, as confirmed by the complete in-
hibition of the response after treatment with the AT
 
1
 
-receptor blocker losartan (Panel B). The AT
 
2
 
-receptor blocker PD 
123319 had no effect. The increase in the chronotropic response induced by IgG isolated at the time of severe rejection 
was similar to the response to angiotensin II (Panel B). Epitope analysis was performed with use of short, overlapping 
peptides corresponding to the second extracellular AT
 
1
 
-receptor loop that were exposed to affinity-purified antibody 
preparations. The sequences AFHYESQ and ENTNIT abolished the chronotropic response (Panel C). The study with 
IgG subclasses (Panel D) indicates that IgG1 and IgG3 harbored AT
 
1
 
-receptor antibodies. IgG2 or IgG4 had no inhibitory 
effect. In Panels B, C, and D, data are represented as means ±SE.
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treated; 23 were refractory to steroids (19.3 percent
of all rejection episodes). Rejection in patients with
donor-specific anti-HLA-antibodies accounted for
9 (39.1 percent) of the 23 steroid-refractory rejection
episodes (7.6 percent of all rejection episodes).
In comparison, rejections in association with
AT
 
1
 
-receptor antibodies had a similar incidence
(10 episodes, accounting for 43.5 percent of ste-
roid-refractory rejection episodes and 8.4 percent
of all rejection episodes). The remaining four ste-
roid-refractory rejection episodes at Charité Cam-
pus Mitte (accounting for 17.4 percent of steroid-
refractory episodes and 3.4 percent of all rejection
episodes) occurred in patients who had neither
AT
 
1
 
-receptor antibodies nor donor-specific anti-
HLA antibodies. The crude prevalence of the rejec-
tion episodes associated with AT
 
1
 
-receptor anti-
bodies (10 among 278 kidney transplantations
performed) during four years was 3.6 percent.
IgG fractions possessing agonistic activity were
used to examine possible epitopes on the second
extracellular loop of the AT
 
1 
 
receptor, to which the
antibodies would bind. Two amino acid sequences,
AFHYESQ and ENTNIT, inhibited the agonistic ac-
tivity of IgG obtained from the patients (Fig. 2C),
indicating that these sites contain the IgG-binding
epitopes for the antibody. Neutralization experi-
ments in which monoclonal antihuman IgG1,
IgG2, IgG3, and IgG4 antibodies were added to
AT
 
1
 
-receptor antibodies demonstrated that anti-
bodies of the IgG1 and IgG3 subclass are responsi-
ble for the agonist-like effect of these antibodies
(Fig. 2D).
The specificity of the bioassay findings was as-
sessed with surface-plasmon-resonance analysis,
which confirmed binding of AT
 
1
 
-receptor antibod-
ies to the peptide of the second extracellular loop of
the AT
 
1 
 
receptor. The BIA evaluation program used
to analyze the results calculated the dissociation
rate constant at 1.05±0.29¬10
 
¡
 
3
 
 per second and
the pseudomolecular association rate constant at
5.02±1.40¬10
 
¡
 
3
 
 per second, revealing a high bind-
ing affinity of AT
 
1
 
-receptor antibodies to the AT
 
1
 
receptor.
Thus, IgG fractions from patients contained
AT
 
1
 
-receptor antibodies of the IgG1 and IgG3 sub-
classes that bound to the second extracellular loop
of the AT
 
1
 
 receptor. Further studies were per-
formed, on the basis of our hypothesis that these
antibodies played a role in the pathogenesis of re-
fractory vascular rejection. Vascular lesions in grafts
that are rejected because of the presence of anti-
HLA antibodies are generally attributed to comple-
ment activation. However, patients with AT
 
1
 
-recep-
tor antibodies did not have complement-fixing cy-
totoxic anti-HLA antibodies in their serum, and
their renal-biopsy specimens generally did not show
staining for C4d. AT
 
1
 
-receptor antibodies were ex-
amined to see whether they could initiate signaling
mediated by ERK 1/2 in vitro by means of endothe-
lial cells and vascular smooth-muscle cells (Fig. 3A
and 3B). AT
 
1
 
-receptor antibody induced phosphor-
ylation of ERK 1/2 (Fig. 3A and 3B), which peaked
at 10 minutes without a change in total ERK 1/2 in
the cells.
We also examined the possibility that the
AT
 
1
 
-receptor antibodies could activate the tran-
 
* P values were determined with use of Fisher’s exact test for categorical varia-
 
bles and the Mann–Whitney U test for continuous variables. 
 
Table 1. Characteristics of Patients with AT
 
1
 
-Receptor Antibodies and Patients 
with Donor-Specific Anti-HLA Antibodies but without AT
 
1
 
-Receptor
Antibodies.
Characteristic
AT
 
1
 
-Receptor
Antibodies
(N=16)
Anti-HLA
Antibodies
(N=13) P Value
 
*
 
Transplant from living donor (no.) 2 4 0.36
Male sex (no.) 10 5 0.12
First kidney allograft (no.) 8 7 1.00
Cold-ischemia time (hr) 0.86
Median 11.2 11.3
Range 1.6–20.0 1.4–16.2
No. of HLA mismatches 0.80
Median 3 3
Range 0–5 2–6
Peak panel-reactive antibodies (%) 0.92
Median 34 30
Range 0–100 0–96
Panel-reactive antibodies at trans-
plantation (%)
0.30
Median 1 0
Range 0–99 0–84
Age at transplantation (yr) 0.38
Median 37.6 44.1
Range 15.1–67.2 20.1–65.2
Time from transplantation to rejec-
tion (days)
0.10
Median 4 9
Range 2–1217 3–680
C4d-positive (no.) 5 13 <0.001
Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at MAX DELBRUECK CENTRUM FOR MOLECULAR MED on February 14, 2005 . 
 n engl j med 
 
352;6
 
www.nejm.org february 
 
10
 
, 
 
2005
 
The
 
 new england journal 
 
of
 
 medicine
 
564
 
scription factor activator protein 1 (AP-1) down-
stream from ERK 1/2 (Fig. 3C). Both AT
 
1
 
-receptor
antibodies and angiotensin II itself induced AP-1
activity in vascular smooth-muscle cells, whereas
control IgG caused no such induction. DNA-bind-
ing activity of nuclear factor-
 
k
 
B (NF-
 
k
 
B), a tran-
scription factor pivotal in initiating immune re-
sponses and inflammatory disease,
 
16
 
 when studied
in nuclear extracts from vascular smooth-muscle
cells, was activated by AT
 
1
 
-receptor antibodies, but
not by IgG from control patients (Fig. 3D).
Tissue factor, which initiates the extrinsic co-
agulation pathway, is a target gene for AP-1 and
NF-
 
k
 
B. Biopsy specimens obtained from patients
during episodes of rejection mediated by AT
 
1
 
-recep-
tor antibodies revealed intense staining of tubular
cells, inflammatory infiltrate, and peritubular cap-
illaries (Fig. 4A). In contrast, only weakly positive
staining was seen in biopsy specimens obtained
after patients had been treated with losartan and
plasmapheresis (Fig. 4B). Treatment consisting
of plasmapheresis, intravenous immune globulin,
and 100 mg of losartan daily in seven patients with
AT
 
1
 
-receptor antibodies resulted in significantly
 
Figure 3. ERK 1/2 Phosphorylation in Endothelial Cells and Vascular Smooth-Muscle Cells and AP-1 and NF-
 
k
 
B Activity 
in Vascular Smooth-Muscle Cells Stimulated with Angiotensin II and Patients’ AT
 
1
 
-Receptor Antibodies.
 
AT
 
1
 
-receptor antibodies (AT
 
1
 
R-AA) stimulate phosphorylation of ERK 1/2 (p-ERK) in endothelial cells (EC, Panel A) and 
vascular smooth-muscle cells (VSMC, Panel B), whereas unphosphorylated ERK 1/2 was not affected in endothelial cells 
and vascular smooth-muscle cells. Incubation with AT1-receptor antibodies increased AP-1–binding activity in a similar 
manner to angiotensin II. A supershift with the antibody against AP-1 subunit c-jun is shown in Panel C. AT1-receptor 
antibodies and angiotensin II result in increased NF-kB DNA-binding activity. A supershifted band was observed with 
the antibodies against NF-kB subunits p50 and p65 (a-p65)in stimulated cells (Panel D).
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improved allograft survival, as compared with that
in patients receiving standard antirejection treat-
ment (Fig. 4C). Serum from four patients with the
longest rejection-free follow-up (who are still re-
ceiving losartan) became negative for AT1-receptor
antibodies (Fig. 4D).
To demonstrate that the agonistic antibodies
could induce vascular rejection, AT1-receptor anti-
bodies were infused into rats that had received
kidney transplants. One week after transplantation,
kidneys from all experimental animals showed evi-
dence of endarteritis and intravascular infiltrates
(Fig. 5A). Transplants from control animals infused
with control IgG showed only endothelial activation
(Fig. 5B). Infusion of AT1-receptor antibodies had
no effect on native kidneys in uninephrectomized
animals (data not shown). The act of transplanting
non-native kidneys into recipients appeared to make
the organs prone to the effects of AT1-receptor anti-
bodies. AT1-receptor antibodies containing human
AT1-receptor–activating antibody–positive IgG but
not control IgG could be detected within the mus-
cular layer of injured arteries in the rats (Fig. 5C
and 5D). The mean arterial pressure, measured by
radiotelemetry, was higher in the group of rats with
AT1-receptor antibodies two weeks after transplan-
tation than in controls (Fig. 5E).
Patients with refractory vascular allograft rejection
and accelerated hypertension but without anti-HLA
discussion
Figure 4. Influence of Losartan and Plasmapheresis Treatment on Tissue-Factor Expression, Allograft Survival, 
and AT1-Receptor–Antibody Activity in AT1-Receptor–Antibody–Positive Rejection.
A representative biopsy specimen obtained at the time of the diagnosis of refractory rejection shows strong epithelial 
and endothelial staining for tissue factor (Panel A). Reduction in tissue factor expression after treatment with losartan 
and plasmapheresis is evident in Panel B. Graft survival in the Kaplan–Meier analysis was significantly increased in the 
patients with AT1-receptor antibodies who received losartan and plasmapheresis, as compared with those who received 
nonspecific treatment (Panel C). Panel D shows decreased activity of AT1-receptor antibodies six months after rejection 
in four patients treated with losartan and plasmapheresis. Values before transplantation and at rejection are shown for 
all AT1-receptor–antibody–positive patients.
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antibodies were found to have pathogenic anti-
bodies directed at two epitopes of the second extra-
cellular loop of the AT1 receptor in their serum.
AT1-receptor antibodies induced phosphorylation
of ERK 1/2, AP-1 activation, and NF-kB activa-
tion in vascular cells. An AT1-receptor antagonist
blocked the effects mediated by AT1-receptor anti-
bodies. Passive infusion of AT1-receptor antibodies
in a rat renal-transplantation model induced vascu-
lar changes and increased blood pressure. These
data suggest that AT1-receptor antibodies may be
directly involved in the pathogenesis of vascular
rejection.
Earlier we had observed AT1-receptor activity
during steroid-refractory, C4d-negative renal-allo-
graft rejection in nine patients with hypertension,
but not in eight patients with steroid-sensitive cel-
lular rejection. In the present study, we increased
the number of patients studied and clearly defined
the pretransplantation activity of IgG1- and IgG3-
subclass antibodies that bound to AT1-receptor
epitopes and induced signaling cascades. The
clinical presentation of transplant recipients with
AT1-receptor antibodies appears similar to that of
transplant recipients with anti-HLA antibodies, but
with significantly worse allograft survival.
Similar agonistic antibodies against the AT1
receptor have been reported in patients with pre-
eclampsia.7 Recently, other investigators confirmed
the existence of AT1-receptor antibodies in patients
with preeclampsia17 and also demonstrated that the
antibodies induced mobilization of intracellular
calcium and activation of a transcription factor,
nuclear factor of activated T cells, in AT1-receptor–
transfected Chinese-hamster-ovary cells.17 The
index patient in the present report had had pre-
eclampsia many years earlier. Nevertheless, the anti-
bodies in this patient and the other transplant re-
cipients bound to an epitope that did not entirely
coincide with the antibodies described earlier in
the patients with preeclampsia.7
Antibodies to G-protein receptors have been
identified in some patients with idiopathic dilated
cardiomyopathy18 or malignant hypertension.19 In
Graves’ disease, autoantibodies activate the thyro-
tropin G-protein receptor, increasing target-organ
activity.20 Anti–endothelial-cell antibodies are non-
HLA antibodies that may be related to the patho-
genesis of allograft rejection.21,22 However, research
on anti–endothelial-cell antibodies is hampered by
the heterogeneity of endothelial cells in various
vascular beds, a fact that makes identifying a stan-
dard detection method difficult.23 Moreover, ini-
tially detected target antigens of anti–endothelial-
cell antibodies were of unclear relevance.23
We suggest that AT1-receptor antibodies have
similarities to anti–endothelial-cell antibodies since
endothelial cells have one AT1 receptor,24 and AT1-
receptor antibodies induced phosphorylation of
ERK 1/2 in endothelial cells. We further suggest
that binding of AT1-receptor antibodies to the AT1
receptor is a critical step for activating the down-
stream signaling cascade, mimicking the action of
angiotensin II and inducing damage to the allo-
graft. Emerging information has established that
angiotensin II acts as an inflammatory cytokine
participating in various vascular disorders.25
AT1-receptor antibodies may induce inflamma-
tory responses and contribute to allograft rejection
by means of activation of NF-kB target genes.
Blockade of NF-kB activity with decoy oligodeoxy-
nucleotides reduced tubulointerstitial infiltration
in rat renal allografts.26 Expression of tissue factor
as regulated by NF-kB and AP-1 may increase pro-
coagulatory activity of the injured vessels.
We previously reported NF-kB and AP-1 sub-
unit expression in biopsy specimens from several
kidney-transplant recipients.8 We now report that
biopsy specimens of patients with rejection associ-
ated with AT1-receptor antibodies had evidence of
increased tissue factor expression and secondary
thrombotic occlusions and that tissue factor was
Figure 5 (facing page). Induction of Acute Vascular Rejec-
tion in Transplant-Recipient Rats Treated with Human 
AT1-Receptor Antibodies and Immunostaining for Human 
AT1-Receptor Antibodies in Injured Vascular Media.
A representative section from a rat allograft seven days 
after transplantation and after seven days of infusion of 
AT1-receptor antibodies shows evidence of endarteritis 
and intravascular inflammatory cells (Panel A, arrow; 
hematoxylin and eosin). No vascular changes occurred 
in rats treated with control IgG (Panel B, hematoxylin and 
eosin). AT1-receptor antibodies were detected in the vas-
cular layer of the injured vessel (arrowheads); arrows show 
fragmentation of the elastic membrane (Panel C, direct 
immunofluorescence). Lack of binding of human control 
IgG in the control group of rats and an intact elastic mem-
brane are evident in Panel D (direct immunofluorescence). 
Radiotelemetric intraaortic recordings show an increase 
in mean arterial pressure in three rats that were infused 
with AT1-receptor antibodies (AT1R-AA), but not in one 
control animal treated with IgG (Panel E). Numbers of 
days before (minus sign) or after (plus sign) transplanta-
tion are shown in the bar graph. I bars indicate SEs.
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reduced after losartan treatment. It has previously
been recognized that the coagulation system has
a role in the pathogenesis of rejection.27 An anti-
cardiolipin antibody–mediated increase in tissue
factor expression contributes to thrombosis in pa-
tients with the antiphospholipid syndrome.28 In rat
cardiac allografts, tissue factor plays a critical role
in clotting abnormalities and transplant arterio-
sclerosis.29 Lesions in allografts in rats infused with
AT1-receptor antibodies resemble those observed
in kidney-transplant recipients.
It is unknown whether AT1-receptor antibodies
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function only through proinflammatory and proco-
agulatory activity or also by means of specific im-
mune responses. Experimental studies have impli-
cated the renin–angiotensin system in the regulation
of the specific immune response and immune-
mediated renal injury.30,31 Since AT1 receptors are
present on human mononuclear cells,32,33 an ef-
fect of AT1-receptor antibodies on T lymphocytes,
monocytes, and dendritic cells appears to be likely.
Furthermore, rejection in association with circulat-
ing anti-HLA antibodies is commonly characterized
by a high incidence of severe vascular lesions with
fibrinoid necrosis, whereas endarteritis and mono-
nuclear cell tubulitis predominate in T-cell–medi-
ated rejection.34
We first observed endarteritis and later fibrinoid
necrosis, tubulitis, and interstitial-cell infiltration in
patients’ biopsy specimens. These characteristics
may define a distinct type of kidney-transplant re-
jection mediated by AT1-receptor antibodies. The
incidence of rejection among patients positive for
AT1-receptor antibodies in this study is similar to
that of rejection due to donor-specific anti-HLA
antibodies. However, it remains unclear why AT1-
receptor antibodies develop in certain patients and
why these antibodies target the allograft.
Molecular mimicry may be important; cross-
reactivity with microbial antigens has an important
role in other pathologic processes associated with
antibodies directed against G-protein receptors —
for example, myasthenia gravis or the dilated car-
diomyopathy seen in Chagas’ disease.35,36 We have
not tested the possibility that the AT1 receptors in
patients in whom AT1-receptor antibodies develop
might harbor specific polymorphisms.37 We spec-
ulate that post-transplantation reperfusion injury
may alter the intragraft expression of AT1 receptor,
change its density, or cause conformational chang-
es. A permissive environmental phenomenon might
enhance local intragraft immunoreactivity owing
to an activated innate immune response.
Transplantation nephrologists have been reluc-
tant to use angiotensin II blockers because of pos-
sible decreases in organ perfusion and filtration.
However, this concern may be outweighed by the
potential advantages of these drugs.38 The seven
patients discussed here who were treated with
losartan, plasmapheresis, and intravenous immu-
noglobulin had amelioration of the antibody-
mediated rejection process and remain free of
rejection while receiving losartan. However, their
treatment was neither randomly assigned nor blind-
ed, and the numbers of patients are too small to
permit us to draw firm conclusions. We speculate
that detection of AT1-receptor antibodies in pa-
tients on a waiting list for a transplant might iden-
tify those at risk for refractory rejection.
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